Expression and Prognostic Relevance of Annexin A3 in Prostate Cancer

European Urology

Volumn 54, Issue 6, 2008, Pages 1314-1323

  Köllermann, Jens ^a   Schlomm, Thorsten ^a   Bang, Holger ^b   Schwall, Gerhard P ^c   von Eichel Streiber, Christoph ^d   Simon, Ronald ^a   Schostak, Martin ^e   Huland, Hartwig ^a   Berg, Wigbert ^b   Sauter, Guido ^a   Klocker, Helmut ^f   Schrattenholz, André ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b ORGenTec Diagnostika GmbH   (Germany)

^c PROTEOSYS AG   (Germany)

^d tgcBIOMICS GmbH   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Annexin A3; Autoimmunity; Benign prostatic disease; Exosomes; Prognosis; Prostate cancer; Risk of progression; Tissue array

Indexed keywords

GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA MICROARRAY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT;

AGED; ANNEXIN A3; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 51349134691     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.01.001     Document Type: Article

References (27)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 56 (2006) 106-130
2. Allsbrook Jr. W.C., Mangold K.A., Johnson M.H., et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 32 (2001) 74-80
3. Djavan B., Kadesky K., Klopukh B., Marberger M., and Roehrborn C.G. Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol 33 (1998) 261-270
4. Gleason D.F. Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions. Urology 47 (1996) 289-291
5. Graefen M., Augustin H., Karakiewicz P.I., et al. Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. Eur Urol 43 (2003) 6-11
6. Kattan M.W., Eastham J.A., Stapleton A.M., Wheeler T.M., and Scardino P.T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766-771
7. Kattan M.W., Potters L., Blasko J.C., et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 58 (2001) 393-399
8. Penson D.F., and Albertsen P.C. Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdom. Surg Oncol 11 (2002) 3-11
9. Stamey T.A. The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA. BJU Int 94 (2004) 963-964
10. Stamey T.A., Johnstone I.M., McNeal J.E., Lu A.Y., and Yemoto C.M. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 167 (2002) 103-111
11. Gerke V., Creutz C.E., and Moss S.E. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 6 (2005) 449-461
12. Radons J., and Multhoff G. Immunostimulatory functions of membrane-bound and exported heat shock protein 70. Exerc Immunol Rev 11 (2005) 17-33
13. Schartz N.E., Chaput N., Andre F., and Zitvogel L. From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes. Curr Opin Mol Ther 4 (2002) 372-381
14. Wozny W., Schroer K., Schwall G., et al. Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3. Proteomics 7 (2007) 313-322
15. Erbersdobler A., Fritz H., Schnöger S., et al. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol 41 (2002) 40-46
16. Bubendorf L., Kononen J., Koivisto P., et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59 (1999) 803-806
17. Kravets F.G., Lee J., Singh B., Trocchia A., Pentyala S.N., and Khan S.A. Prostasomes: current concepts. Prostate 43 (2000) 169-174
18. Pisitkun T., Shen R.F., and Knepper M.A. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A 101 (2004) 13368-13373
19. Yang Y., Xiu F., Cai Z., et al. Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells. J Cancer Res Clin Oncol 133 (2007) 389-399
20. Wozny W., Schroer K., Schwall G.P., et al. Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3. Proteomics 7 (2007) 313-322
21. Minelli A., Ronquist G., Carlsson L., Mearini E., Nilsson O., and Larsson A. Antiprostasome antibody titres in benign and malignant prostate disease. Anticancer Res 25 (2005) 4399-4402
22. Larsson A., Ronquist G., Wulfing C., et al. Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability. Urol Oncol 24 (2006) 195-200
23. Park J.E., Lee D.H., Lee J.A., et al. Annexin A3 is a potential angiogenic mediator. Biochem Biophys Res Commun 337 (2005) 1283-1287
24. Rubin M.A., Dunn R., Strawderman M., and Pienta K.J. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26 (2002) 312-319
25. Torhorst J., Bucher C., Kononen J., et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159 (2001) 2249-2256
26. Moch H., Kononen T., Kallioniemi O.P., and Sauter G. Tissue microarrays: what will they bring to molecular and anatomic pathology?. Adv Anat Pathol 8 (2001) 14-20
27. Wagner U., Sauter G., Moch H., et al. Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Hum Pathol 26 (1995) 970-978